The body's skin and tissues can't adapt fast enough to the velocity of loss.
Across clinics in the UK and beyond, a quiet consequence of the weight-loss drug revolution is making itself felt underfoot — literally. As millions turn to GLP-1 injections like Ozempic and Mounjaro to shed weight rapidly, the fat pads that cushion the soles of their feet are disappearing along with the pounds, leaving skin sagging, joints exposed, and walking painful. The condition, now named 'Ozempic feet,' joins a growing catalogue of unintended costs that accompany one of modern medicine's most celebrated interventions, reminding us that the body's systems are rarely transformed without consequence elsewhere.
- Patients arriving at clinics with mysterious foot pain are discovering that the very injections meant to improve their health are stripping away the natural cushioning that makes walking bearable.
- The problem is sharpest among privately prescribed users with lower BMIs, where rapid, dramatic fat loss outpaces the body's ability to adapt — and many never connect their aching feet to their weight-loss jabs.
- With over 15 million users in the US and nearly 2.5 million in the UK, the sheer scale of GLP-1 drug adoption means even rare side effects are now arriving in volume at doctors' doors.
- Treatments exist — collagen stimulants for cosmetic sagging around £200, and dermal fillers to restore lost cushioning and relieve pain — but they only hold if the patient's weight has first stabilised.
- Ozempic feet joins a lengthening list of side effects including hair thinning, receding gums, and the hollowed 'Ozempic face,' complicating the narrative of these drugs as straightforward medical breakthroughs.
Doctors are reporting a sharp rise in patients whose feet have become painful, not from injury, but from the weight-loss injections they hoped would improve their lives. The condition — now called 'Ozempic feet' — occurs when rapid fat loss from drugs like Ozempic and Mounjaro depletes the natural cushioning beneath the soles and toes, leaving joints under pressure and skin sagging prematurely. The feet can age visibly, with thin, dehydrated skin and prominent veins, distressing patients aesthetically as much as physically.
Aesthetic specialist Dr. Bhavik Shah has seen the surge firsthand over the past 18 months. The problem is especially common among those who obtained the injections privately — often people with lower BMIs than the drugs are typically prescribed for — where the speed of fat loss overwhelms the body's capacity to adapt. Many patients don't initially blame the injections at all, attributing their foot pain to increased exercise or simply not mentioning their medication to clinicians.
The condition has historical echoes: a decade ago, dermatologists treated similar fat-pad depletion caused by high heels. That problem faded as fashion changed. Now it has returned, driven by the explosive growth of weight-loss drugs used by some 15 million Americans and up to 2.5 million people in the UK.
Treatment options include collagen-stimulating injections for cosmetic concerns and hyaluronic acid dermal fillers to restore lost volume and relieve pain — results that can last up to two years, but only if the patient's weight has stabilised first. Shah is clear: ongoing weight loss will undo any intervention.
The broader picture remains complex. These drugs have delivered genuine benefit to many, but their side-effect profile keeps expanding — hair loss, receding gums, gastrointestinal problems, and the hollowed 'Ozempic face' among them. NHS prescriptions have risen nearly tenfold since 2020, and demand shows no sign of slowing. The question medicine now faces is how to manage the full range of consequences — visible, painful, and otherwise — that accompany one of the most widely adopted pharmaceutical interventions in recent memory.
Doctors across the country are seeing a sharp rise in patients arriving with a peculiar problem: their feet hurt. The pain comes not from injury or disease, but from the very thing meant to help them—weight-loss injections like Ozempic and Mounjaro that have become ubiquitous in private clinics and increasingly on the NHS. The condition, now called 'Ozempic feet,' emerges when rapid fat loss strips away the natural cushioning beneath the skin of the soles and toes, leaving joints bearing more pressure than they were designed to handle. The skin itself sags and wrinkles prematurely, aging the feet in ways that distress patients as much as the physical discomfort does.
Dr. Bhavik Shah, an aesthetic specialist, has witnessed the surge firsthand. Over the past 18 months, his practice has fielded a steady stream of patients complaining of soreness on the soles of their feet, pain around the bony prominences, and skin that looks thin, dehydrated, and webbed with visible veins. Left untreated, he notes, the condition can make walking genuinely difficult. The problem is especially pronounced among those who obtained the injections privately—often people with body mass indices lower than the drugs are typically prescribed for. In these cases, the speed and magnitude of fat loss overwhelms the body's ability to adapt. Many patients, Shah observes, don't immediately blame the injections. Some attribute the foot pain to increased activity, which is indeed part of weight management. Others simply don't mention their use of the medication to clinicians, leaving doctors to puzzle over the cause.
The condition itself is not entirely new. A decade ago, when high heels dominated fashion, dermatologists treated similar problems regularly. The pressure of heels compressed and displaced the natural fat pad on the foot, thinning it and causing pain and calluses. As footwear trends shifted, the problem largely vanished. Now it has returned, driven not by fashion but by the explosive growth of weight-loss drugs. At least half a million NHS patients are now using these injections, with roughly 1.5 to 2.5 million across the UK overall. In the United States, the numbers are far larger—some 15 million people, with tens of millions more taking GLP-1 drugs for diabetes control. The drugs work by mimicking hormones that suppress appetite and slow digestion, allowing users to feel full longer. In clinical trials, semaglutide produced average weight loss of 15 to 20 percent over 68 to 88 weeks, while newer formulations have achieved even steeper reductions.
Treatment options exist, though they come with their own costs and limitations. For patients whose concern is purely cosmetic—sagging skin and prematurely aged feet without pain—collagen-stimulating injections offer a solution. These cost around £200 and work by encouraging the body to produce more collagen, the protein that keeps skin firm and elastic. For those experiencing actual pain or discomfort, dermal fillers become necessary. These injections, typically made from hyaluronic acid, restore lost volume and cushioning by replacing the fat that the weight-loss drugs have burned away. The procedure can last up to two years, depending on the filler type and individual metabolism. But Shah emphasizes a crucial condition: the patient's weight must have stabilized. If someone is still losing weight, the results won't hold, and treatment will need repeating.
The broader picture of these drugs remains complicated. They have been hailed as medical breakthroughs, and for many people they deliver genuine benefit. But the list of side effects continues to grow. Beyond 'Ozempic feet,' users report thinning hair, receding gums, and the well-documented 'Ozempic face'—a hollowed, aged appearance in the cheeks and jawline. More serious risks include gastrointestinal problems, pancreatitis, gallbladder disease, and in rare cases, acute kidney injury. Weight often returns once treatment stops, and real-world results tend to be more modest than clinical trials suggest, partly because patients discontinue early or reduce doses. Yet demand shows no sign of slowing. In the UK, NHS prescriptions have risen nearly tenfold since 2020. The question now is not whether these drugs will remain popular, but how medicine will manage the full spectrum of consequences—visible, painful, and otherwise—that come with them.
Citações Notáveis
In the last year to 18 months we've seen a dramatic rise in patients coming in with this problem. Patients often complain of discomfort on the soles of their feet, and if left untreated it can lead to real pain when walking.— Dr. Bhavik Shah, aesthetic specialist
The key is that the patient's weight has stabilised—otherwise the results won't last and the treatment will need to be repeated.— Dr. Bhavik Shah
A Conversa do Hearth Outra perspectiva sobre a história
Why are doctors seeing this now, all of a sudden? Didn't people lose weight rapidly before these drugs existed?
They did, but not at this scale or speed. These injections compress months of weight loss into weeks. The body's skin and tissues can't adapt fast enough. It's the velocity that matters.
And the feet specifically—why there and not, say, the face or hands?
The feet bear your weight. When the fat pad underneath thins, the bones and joints suddenly experience pressure they're not cushioned for anymore. It's biomechanical. The face changes too, but the feet actually hurt.
The doctor mentioned that people on these drugs privately often have lower BMIs than recommended. Why would that happen?
Because there's no gatekeeper in private medicine. If you have money and want to lose weight faster, a clinic will prescribe it. The drugs work regardless of where you start. But if you're already lean, losing fat rapidly means losing essential cushioning.
Can you reverse it?
Not entirely. You can inject fillers to restore cushioning, but that's maintenance, not reversal. And it only works if your weight stays stable. If you keep losing weight, you'll need more injections.
So in a way, the treatment becomes another ongoing medical intervention.
Exactly. You trade one pharmaceutical dependency for another—or add to it. That's the part people don't always think through when they start.